skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Total Skin Electron Therapy for Cutaneous T-Cell Lymphoma Using a Modern Dual-Field Rotational Technique

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1];  [2];  [3];  [4];  [2];  [5]; ;  [2]
  1. Emory University School of Medicine, Emory University, Atlanta, Georgia (United States)
  2. Department of Radiation Oncology, Emory University, Atlanta, Georgia (United States)
  3. Department of Dermatology, Emory University, Atlanta, Georgia (United States)
  4. Biostatistics Shared Core Resource at WCI, Emory University, Atlanta, Georgia (United States)
  5. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia (United States)

Purpose: To report our experience with rotational total skin electron irradiation (RTSEI) in cutaneous T-cell lymphoma (CTCL), and to examine response by disease stage and race. Methods and Materials: We reviewed our outcomes for 68 CTCL patients who received RTSEI (≥30 Gy) from 2000 to 2013. Primary outcomes were complete clinical response (CCR), recurrence-free survival (RFS), and overall survival (OS). Using log–rank tests and Cox proportional hazards, OS and RFS were compared across tumor stages at time of RTSEI with further racial subgroup analysis. Results: Median age at diagnosis and at time of radiation was 52 and 56 years, respectively. Median follow-up was 5.1 years, 49% were African American, and 49% were female. At time of treatment, 18, 37, and 13 patients were T stage 2, 3, and 4, respectively. At 6 weeks after RTSEI, overall CCR was 82% (88%, 83%, and 69% for T2, T3, and T4, respectively). Median RFS was 11 months for all patients and 14, 10, and 12 months for stage T2, T3, and T4, respectively. Tumor stage was not associated with RFS or CCR. Maintenance therapy after RTSEI was associated with improved RFS in both crude and multivariable analysis, controlling for T stage. Median OS was 76 months (91 and 59 months for T3 and T4, respectively). With the exception of improved OS in African Americans compared with whites at stage T2, race was not associated with CCR, RFS, or OS. Conclusions: These results represent the largest RTSEI clinical outcomes study in the modern era using a dual-field rotational technique. Our observed response rates match or improve upon the standard set by previous outcome studies using conventional TSEI techniques, despite a large percentage of advanced CTCL lesions in our cohort. We found that clinical response after RTSEI did not seem to be affected by T stage or race.

OSTI ID:
22458710
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 92, Issue 1; Other Information: Copyright (c) 2015 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

Role of Brachytherapy in the Boost Management of Anal Carcinoma With Node Involvement (CORS-03 Study)
Journal Article · Fri Mar 01 00:00:00 EST 2013 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22458710

Role of Adjuvant Chemoradiation Therapy in Adenocarcinomas of the Ampulla of Vater
Journal Article · Sat Mar 01 00:00:00 EST 2008 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22458710

Adaptive Radiotherapy for Head-and-Neck Cancer: Initial Clinical Outcomes From a Prospective Trial
Journal Article · Sun Jul 01 00:00:00 EDT 2012 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22458710